Luiz Alcino Gueiros, Margherita Gobbo, Alan Roger Santos-Silva, Elisabetta Merigo, Wanessa Miranda-Silva, Eduardo Rodrigues Fregnani, Giulia Ottaviani, Elisa Kauark-Fontes, Rene-Jean Bensadoun, Praveen Arany
{"title":"Underexplored Areas of Photobiomodulation in Oral Oncology: An Expert Analysis.","authors":"Luiz Alcino Gueiros, Margherita Gobbo, Alan Roger Santos-Silva, Elisabetta Merigo, Wanessa Miranda-Silva, Eduardo Rodrigues Fregnani, Giulia Ottaviani, Elisa Kauark-Fontes, Rene-Jean Bensadoun, Praveen Arany","doi":"10.1089/photob.2023.0155","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> This study aimed to review the current body of literature on underexplored areas of photobiomodulation (PBM) for preventing and/or treating oral adverse events. <b><i>Background:</i></b> Recent studies suggest that PBM may offer potential benefits in managing cancer-related toxicities other than oral mucositis. Nevertheless, further research to establish conclusive evidence is still missing. <b><i>Methods:</i></b> A panel of specialists conducted a narrative review to evaluate the evidence on PBM therapy for oral mucositis, xerostomia, dysgeusia, dysphagia, and trismus/fibrosis. Each topic was reviewed by two specialists who discussed treatment rationale, summarized current evidence, evaluated risk/benefit ratio, and identified future research directions. <b><i>Results:</i></b> The current evidence suggests promising outcomes in nonroutine uses of PBM for xerostomia, dysgeusia, odynophagia, oral mucositis (extraoral PBM and the pediatric population), and trismus/fibrosis. However, the primary studies are often small and may have biases that require further evaluation, particularly regarding treatment safety. <b><i>Conclusion:</i></b> Despite the overall positive impression of PBM therapy for oral adverse events of cancer treatment, robust evidence from large multicentered studies is necessary to support its widespread clinical use.</p>","PeriodicalId":94169,"journal":{"name":"Photobiomodulation, photomedicine, and laser surgery","volume":"42 10","pages":"609-619"},"PeriodicalIF":1.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Photobiomodulation, photomedicine, and laser surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/photob.2023.0155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aimed to review the current body of literature on underexplored areas of photobiomodulation (PBM) for preventing and/or treating oral adverse events. Background: Recent studies suggest that PBM may offer potential benefits in managing cancer-related toxicities other than oral mucositis. Nevertheless, further research to establish conclusive evidence is still missing. Methods: A panel of specialists conducted a narrative review to evaluate the evidence on PBM therapy for oral mucositis, xerostomia, dysgeusia, dysphagia, and trismus/fibrosis. Each topic was reviewed by two specialists who discussed treatment rationale, summarized current evidence, evaluated risk/benefit ratio, and identified future research directions. Results: The current evidence suggests promising outcomes in nonroutine uses of PBM for xerostomia, dysgeusia, odynophagia, oral mucositis (extraoral PBM and the pediatric population), and trismus/fibrosis. However, the primary studies are often small and may have biases that require further evaluation, particularly regarding treatment safety. Conclusion: Despite the overall positive impression of PBM therapy for oral adverse events of cancer treatment, robust evidence from large multicentered studies is necessary to support its widespread clinical use.